Heart failure & cardiomyopathies
Microbially Produced Imidazole Propionate Is Associated With Heart Failure and Mortality
Main finding · 5-year mortality (North American cohort)Result — go to the resultAdjusted hazard ratio 1.85 95% CI 1.20–2.88Authors' conclusion
The gut microbial metabolite ImP is increased in individuals with heart failure and is a predictor of overall survival.
Study context
- Population
- Patients with a range of severity of CVD including HF2 cohorts
- Participants
- 1,985 vs 2,155
- Exposure
- Serum imidazole propionate (ImP) levels
- Europeann = 1,985
- North Americann = 2,155
- Outcome
- Association of ImP with HF and mortality
- Follow-up
- 5 years (mortality)
Methodological details2 independent clinical cohorts
- 2 independent clinical cohorts
Main finding
5-year mortality (North American cohort) · 5 years
Adjusted hazard ratio
1.85
95% CI 1.20–2.88
P < 0.01
Serum ImP levels (highest quartile vs lower)
adjusted HR 1.85 (95% CI 1.20–2.88); P < 0.01
As reported in the abstract
Observational data: associations, not effects.
Original publication
Microbially Produced Imidazole Propionate Is Associated With Heart Failure and Mortality. JACC Heart Fail. Published 26 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →